›› 2012, Vol. 32 ›› Issue (2): 226-.doi: 10.3969/j.issn.1674-8115.2012.02.022
• Review • Previous Articles Next Articles
SUO Yan, LIU Kun, XU Xun
Online:
Published:
Supported by:
Shanghai Key Laboratory for Ocular Fundus Diseases Foundation, 07Z22911
Abstract:
Diabetic macular edema (DME) is one of the major causes of visual impairment in patients with diabetes mellitus. The major treatment methods for DME include laser photocoagulation therapy, anti-inflammatory therapy and anti-vascular endothelial growth factor (VEGF) therapy. In recent years, anti-VEGF drugs such as Ranibizumab, Bevacizumab, VEGF-Trap and KH902 have exhibited favorable effects in treatment of DME. The research progress of anti-VEGF therapy for DME is reviewed in this paper, and the efficacy and safety of anti-VEGF therapy are explored.
Key words: diabetic macular edema, laser photocoagulation, anti-inflammatory therapy, anti-vascular endothelial growth factor drug
SUO Yan, LIU Kun, XU Xun. Update on anti-vascular endothelial growth factor treatment for diabetic macular edema[J]. , 2012, 32(2): 226-.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2012.02.022
https://xuebao.shsmu.edu.cn/EN/Y2012/V32/I2/226